Literature DB >> 9740198

Nutrient intake and growth of infants with phenylketonuria undergoing therapy.

P B Acosta1, S Yannicelli, B Marriage, C Mantia, B Gaffield, M Porterfield, M Hunt, N McMaster, L Bernstein, P Parton, M Kuehn, V Lewis.   

Abstract

BACKGROUND: Because of reports of poor growth, a study was conducted for 6 months in 35 infants with classic phenylketonuria diagnosed during the neonatal period who were fed Phenex-1 Amino Acid Modified Medical Food With Iron (Ross Products Division, Columbus, OH, U.S.A.).as their primary protein source.
METHODS: Diet diaries and anthropometric measures were obtained monthly as part of a larger study in which nutrition status was evaluated.
RESULTS: In 6-month-old infants, mean percentiles for crown-heel length (59.14+/-4.31 SEM), head circumference (63.88+/-4.50) and weight (71.51+/-4.25) were normal. Mean (+/- SEM) daily intake of medical food was 79+/-4 g; protein and energy intakes were 17.3+/-0.6 g and 2772+/-75.6 kJ (660+/-18 kcal). Mean daily phenylalanine and tyrosine intakes per kilogram of body weight were 40+/-1 mg and 219+/-9 mg. Intakes of protein, energy, and tyrosine were positively correlated with crown-heel length, head circumference, and weight at 3 months of study. Overall plasma phenylalanine and tyrosine concentrations during the 6-month study were 297+/-41 micromol/l and 58+/-5 micromol/l, respectively. Neither plasma phenylalanine nor tyrosine concentration was correlated with growth.
CONCLUSION: Phenex-1 supports normal growth when fed in adequate amounts. These data support those of the Medical Research Council Working Party on Phenylketonuria for 3 g/kg per day of amino acids from medical food.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740198     DOI: 10.1097/00005176-199809000-00003

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  13 in total

1.  The intake of total protein, natural protein and protein substitute and growth of height and head circumference in Dutch infants with phenylketonuria.

Authors:  M Hoeksma; M Van Rijn; P H Verkerk; A M Bosch; M F Mulder; J B C de Klerk; T J de Koning; E Rubio-Gozalbo; M de Vries; P J J Sauer; F J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

Authors:  S Yannicelli; D M Medeiros
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

3.  Using change in plasma phenylalanine concentrations and ability to liberalize diet to classify responsiveness to tetrahydrobiopterin therapy in patients with phenylketonuria.

Authors:  Rani H Singh; Meghan E Quirk
Journal:  Mol Genet Metab       Date:  2011-09-16       Impact factor: 4.797

4.  Transition of young adults with phenylketonuria from pediatric to adult care.

Authors:  Ulrike Mütze; Annika Roth; Johannes F W Weigel; Skadi Beblo; Christoph G Baerwald; Peter Bührdel; Wieland Kiess
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

Review 5.  Protein substitutes for PKU: what's new?

Authors:  A Macdonald; A Daly; P Davies; D Asplin; S K Hall; G Rylance; A Chakrapani
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 6.  Growth and body composition in children with classical phenylketonuria: results in 34 patients and review of the literature.

Authors:  M Huemer; C Huemer; D Möslinger; D Huter; S Stöckler-Ipsiroglu
Journal:  J Inherit Metab Dis       Date:  2007-07-11       Impact factor: 4.982

Review 7.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

8.  Chronic kidney disease in adolescent and adult patients with phenylketonuria.

Authors:  Julia B Hennermann; Sylvia Roloff; Jutta Gellermann; Ilka Vollmer; Elke Windt; Barbara Vetter; Ursula Plöckinger; Eberhard Mönch; Uwe Querfeld
Journal:  J Inherit Metab Dis       Date:  2012-11-09       Impact factor: 4.982

Review 9.  Mild hyperphenylalaninemia: to treat or not to treat.

Authors:  Francjan J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2011-02-24       Impact factor: 4.982

10.  A long-term study of bone mineral density in patients with phenylketonuria under diet therapy.

Authors:  Hala M Koura; Nagwa Abdallah Ismail; Ashraf F Kamel; Azza M Ahmed; Amal Saad-Hussein; Laila K Effat
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.